Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 574

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Eliza A Hawkes, Hui-Peng Lee, MBChB, FRACP, FRCPA, BHB, Tara Cochrane, MBBS,FRCPA,FRACP, Chan Y. Cheah, Duncan Purtill, MBBS,FRCPA,FRACP, Anoop K Enjeti, MBBS,FRCPA, FRACP,PhDMD,MRCP, Christina Brown, PhDFRACP,FRCPA,MBBS, Nicholas E. Murphy, FRCPA,MBBS,FRACP, Jennifer Curnow, MBBS, FRACP, FRCPA, PhD, Julia Carlson, Belinda Butcher, BSci, MBiostat, PhD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4094.

https://doi.org/10.1182/blood-2019-124621

Published: 2019

Journal Articles

Quality of Life Impairment in Adult Patients with ACUTE Lymphoblastic Leukemia with Minimal Residual Disease in France

Stephane Lepretre, MD, Chantal Touboul, Alain Flinois, PhD, Lucie Kutikova, PhD, Kahina Makhloufi, MD, Jean-Vannak Chauny, PharmD, Gaëlle Désaméricq

Blood (2019) 134 (Supplement_1): 5123.

https://doi.org/10.1182/blood-2019-122466

Published: 2019

Journal Articles

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

Adi Shacham, MD, Lena Rosenman, Avi Leader, MD, Giora Sharf, Pia Raanani, MD, Uri Rozovski, MD

Blood (2019) 134 (Supplement_1): 4781.

https://doi.org/10.1182/blood-2019-129806

Published: 2019

Journal Articles

Under Reporting of Patient Reported Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials

Anthony J Messina, MSc, Quentin E O'Brien, MPH, Vasily Andrianov, MD, Keren R. Moss, MD, Laura Vidal, MD, Liat Vidal-Fisher, MD MSc

Blood (2019) 134 (Supplement_1): 4754.

https://doi.org/10.1182/blood-2019-128741

Published: 2019

Journal Articles

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Angela Molga, MBBS, Michelle Wall, Dip HE (Nursing), BA (Hons), MSc, PG Cert, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Deepak Singhal, MBBS, MDFRACP, FRCPA, Pratyush Giri, MBBS,FRACP,FRCPA, Timothy To, BSc, BMBS, FRACP, FAChPM, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 5426.

https://doi.org/10.1182/blood-2019-132164

Published: 2019

Journal Articles

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Jennifer Woyach, MD, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Eric McLaughlin, MS, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Michael Keller, Matthew Dort, Gerard Lozanski, MD, Barbara Andersen, PhD, John C. Byrd, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 1759.

https://doi.org/10.1182/blood-2019-131099

Published: 2019

Journal Articles

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Pushpendra Goswami, PhD MSc, BPharm, Tatiana Ionova, DSc, Esther Natalie Oliva, PhD, Roger Else, Jonathan Kell, MD, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Daniel Jennings, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Stewart McConnell, Catherine Langton, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2019) 134 (Supplement_1): 3484.

https://doi.org/10.1182/blood-2019-129030

Published: 2019

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study

Katherine Houghton, MSc, BSc, Meletios A. Dimopoulos, MD, Peggy Lin, PhD, Sophie Guillonneau, MSc, Denise Bury, MPH, PhD, Michel Attal, MD PhD, Paul G. Richardson, MD, Michel Delforge, MD PhD

Blood (2019) 134 (Supplement_1): 1850.

https://doi.org/10.1182/blood-2019-128220

Published: 2019

Journal Articles

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Blood (2019) 134 (Supplement_1): 117.

https://doi.org/10.1182/blood-2019-125562

Published: 2019

Journal Articles

Invasive Fungal Diseases Caused By Rare Pathogens in Large Cohort of Pediatric and Adult Patients after Hematopoietic Stem Cell Transplantation and Chemotherapy

Blood (2019) 134 (Supplement_1): 4497.

https://doi.org/10.1182/blood-2019-127961

Published: 2019

Journal Articles

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

Matthew Wilson, MD BSc, MRCP, Catherine Ogilvie, MD, Jennifer Travers, MD, Michelle Martin, Jonathan Allan, Pam McKay, MD, Mike Leach, MD

Blood (2019) 134 (Supplement_1): 5285.

https://doi.org/10.1182/blood-2019-126704

Published: 2019

Journal Articles

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Cristina Gasparetto, MD, Rakesh Popat, Shaji K. Kumar, MD, Michele Cavo, Javier de la Rubia, MD PhD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, James Maciel, Liang-Tsai Hsiao, Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Jia Jia, PhD MBA, Sudeep Karve, PhD, Esprit Ma, Jacob Devine, MA, Katy Benjamin

Blood (2019) 134 (Supplement_1): 3177.

https://doi.org/10.1182/blood-2019-127387

Published: 2019

Journal Articles

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Sherief El- Shakankery, MPharm, Sumantha Gabriel, BPharm, Emma Groves, M Pharm

Blood (2019) 134 (Supplement_1): 5887.

https://doi.org/10.1182/blood-2019-124329

Published: 2019

Journal Articles

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Manju Sengar, MD DM, Mounika Boppana, MD DM, Hasmukh Jain, MD DM, Vikram Gota, MD, Bhausaheb Bagal, MD DM, Anant Gokarn, MD, Murari Gujrar, MD, Madhavi Ambotkar, MD

Blood (2019) 134 (Supplement_1): 2600.

https://doi.org/10.1182/blood-2019-129948

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Blood (2019) 134 (Supplement_1): 2618.

https://doi.org/10.1182/blood-2019-130642

Published: 2019

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

David Cella, PhD, Jan McKendrick, Harrison Davis, Ravi Vij, MBBS, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2190.

https://doi.org/10.1182/blood-2019-122668

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

NARROW

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Quality of Life Impairment in Adult Patients with ACUTE Lymphoblastic Leukemia with Minimal Residual Disease in France

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

Under Reporting of Patient Reported Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials

An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study

Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial

Invasive Fungal Diseases Caused By Rare Pathogens in Large Cohort of Pediatric and Adult Patients after Hematopoietic Stem Cell Transplantation and Chemotherapy

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Single Arm, Single Centre Prospective Study to Assess the Effect of Therapeutic Drug Monitoring (TDM) Based Dosage Adjustment of Posaconazole on the Incidence of Invasive Fungal Infections (IFIs) in AML Patients on Induction Chemotherapy on Posaconazole Prophylaxis

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only